{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:02:31Z","timestamp":1780628551072,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00473-3","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:26:06Z","timestamp":1776925566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies"],"prefix":"10.1186","volume":"12","author":[{"given":"Simona","family":"Chiusolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Kriesberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Oligino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Abdel-Qadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Casselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"issue":"6","key":"473_CR1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost. 2023;21(6):1397\u2013408.","journal-title":"J Thromb Haemost"},{"key":"473_CR2","doi-asserted-by":"publisher","unstructured":"Abdol Razak NB, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10):380. https:\/\/doi.org\/10.3390\/cancers10100380.","DOI":"10.3390\/cancers10100380"},{"key":"473_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","volume":"225","author":"AS Kim","year":"2020","unstructured":"Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33\u201353.","journal-title":"Transl Res"},{"key":"473_CR4","doi-asserted-by":"publisher","unstructured":"CJ, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151). https:\/\/doi.org\/10.1183\/16000617.0119-2018.","DOI":"10.1183\/16000617.0119-2018"},{"issue":"5","key":"473_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12185-024-03735-x","volume":"119","author":"K Tatsumi","year":"2024","unstructured":"Tatsumi K. The pathogenesis of cancer-associated thrombosis. Int J Hematol. 2024;119(5):495\u2013504.","journal-title":"Int J Hematol"},{"key":"473_CR6","doi-asserted-by":"publisher","first-page":"108116","DOI":"10.1016\/j.pharmthera.2022.108116","volume":"237","author":"JD Terwoord","year":"2022","unstructured":"Terwoord JD, Beyer AM, Gutterman DD. Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacol Ther. 2022;237:108116.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"473_CR7","doi-asserted-by":"publisher","first-page":"e12763","DOI":"10.1002\/rth2.12763","volume":"6","author":"C LaVasseur","year":"2022","unstructured":"LaVasseur C, et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost. 2022;6(6):e12763.","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"473_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1538-7836.2010.04126.x","volume":"9","author":"W Saber","year":"2011","unstructured":"Saber W, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312\u20139.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"473_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1186\/s12885-022-09944-z","volume":"22","author":"C O\u2019Neill","year":"2022","unstructured":"O\u2019Neill C, et al. Survival of cancer patients with pre-existing heart disease. BMC Cancer. 2022;22(1):847.","journal-title":"BMC Cancer"},{"issue":"7","key":"473_CR10","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334\u201347.","journal-title":"Lancet Oncol"},{"issue":"41","key":"473_CR11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u20134361.","journal-title":"Eur Heart J"},{"issue":"10","key":"473_CR12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612\u201376.","journal-title":"Europace"},{"issue":"6","key":"473_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","volume":"104","author":"FI Mulder","year":"2019","unstructured":"Mulder FI, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277\u201387.","journal-title":"Haematologica"},{"issue":"10","key":"473_CR14","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902\u20137.","journal-title":"Blood"},{"issue":"16","key":"473_CR15","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.22.01542","volume":"41","author":"A Li","year":"2023","unstructured":"Li A, et al. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023;41(16):2926\u201338.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"473_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2024-202183","volume":"144","author":"A Li","year":"2024","unstructured":"Li A, et al. External Validation of EHR-CAT Risk Assessment Model for Cancer Associated Thrombosis in 150 Healthcare Organizations. Blood. 2024;144(Supplement 1):812\u2013812.","journal-title":"Blood"},{"key":"473_CR17","doi-asserted-by":"publisher","first-page":"107602962110459","DOI":"10.1177\/10760296211045908","volume":"27","author":"H Abdel-Razeq","year":"2021","unstructured":"Abdel-Razeq H, et al. The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma. Clin Appl Thromb Hemost. 2021;27:10760296211045908.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"473_CR18","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cam4.1540","volume":"7","author":"J Rupa-Matysek","year":"2018","unstructured":"Rupa-Matysek J, et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med. 2018;7(7):2868\u201375.","journal-title":"Cancer Med"},{"issue":"16","key":"473_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.22.00255","volume":"41","author":"A Mu\u00f1oz","year":"2023","unstructured":"Mu\u00f1oz A, et al. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. J Clin Oncol. 2023;41(16):2911\u201325.","journal-title":"J Clin Oncol"},{"issue":"6","key":"473_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.12474","volume":"162","author":"J Murray","year":"2013","unstructured":"Murray J, Precious E, Alikhan R. Catheter-related thrombosis in cancer patients. Br J Haematol. 2013;162(6):748\u201357.","journal-title":"Br J Haematol"},{"issue":"10","key":"473_CR21","first-page":"8577","volume":"30","author":"JC Laguna","year":"2022","unstructured":"Laguna JC, et al. Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care. Support Care Cancer. 2022;30(10):8577\u201388.","journal-title":"Support Care Cancer"},{"issue":"4","key":"473_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374.","journal-title":"Blood Adv"},{"issue":"11","key":"473_CR23","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","volume":"73","author":"RC Mosarla","year":"2019","unstructured":"Mosarla RC, et al. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(11):1336\u201349.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"473_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1055\/s-0040-1710016","volume":"120","author":"RJ Morris","year":"2020","unstructured":"Morris RJ, Roberts CH. Haematological Effects of Intermittent Pneumatic Compression for Deep Vein Thrombosis Prophylaxis. Thromb Haemost. 2020;120(6):912\u201323.","journal-title":"Thromb Haemost"},{"issue":"4","key":"473_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543\u2013603.","journal-title":"Eur Heart J"},{"issue":"2","key":"473_CR26","first-page":"99","volume":"11","author":"F Kaghazchi","year":"2021","unstructured":"Kaghazchi F, et al. Venous thromboembolism detected by FDG-PET\/CT in cancer patients: a common, yet life-threatening observation. Am J Nucl Med Mol Imaging. 2021;11(2):99\u2013106.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"473_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1742271X15625432","volume":"24","author":"A Smith","year":"2016","unstructured":"Smith A, et al. Contrast sonovenography - Is this the answer to complex deep vein thrombosis imaging? Ultrasound. 2016;24(1):17\u201322.","journal-title":"Ultrasound"},{"issue":"5","key":"473_CR28","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3390\/tomography9050154","volume":"9","author":"L Cerrito","year":"2023","unstructured":"Cerrito L, et al. The Role of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Neoplastic Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma. Tomography. 2023;9(5):1976\u201386.","journal-title":"Tomography"},{"issue":"11","key":"473_CR29","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1160\/TH17-05-0332","volume":"117","author":"M Kaspar","year":"2017","unstructured":"Kaspar M, et al. Perivascular Perfusion on Contrast-Enhanced Ultrasound (CEUS) Is Associated with Inflammation in Patients with Acute Deep Vein Thrombosis. Thromb Haemost. 2017;117(11):2146\u201355.","journal-title":"Thromb Haemost"},{"issue":"9","key":"473_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.echo.2023.05.003","volume":"36","author":"S Shah","year":"2023","unstructured":"Shah S, et al. A Multimodality Imaging Approach to Defining Risk in Patients With Acute Pulmonary Embolism. J Am Soc Echocardiogr. 2023;36(9):933\u201340.","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"473_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ajh.25482","volume":"94","author":"ED Johnson","year":"2019","unstructured":"Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. Am J Hematol. 2019;94(7):833\u20139.","journal-title":"Am J Hematol"},{"issue":"1144","key":"473_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/postgradmedj-2019-137123","volume":"97","author":"J Lim","year":"2021","unstructured":"Lim J, Cardle C, Isles C. Patients with markedly elevated D-dimer who do not have pulmonary embolism. Postgrad Med J. 2021;97(1144):77\u201382.","journal-title":"Postgrad Med J"},{"issue":"21","key":"473_CR33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1001\/jama.2021.20750","volume":"326","author":"Y Freund","year":"2021","unstructured":"Freund Y, et al. Effect of a Diagnostic Strategy Using an Elevated and Age-Adjusted D-Dimer Threshold on Thromboembolic Events in Emergency Department Patients With Suspected Pulmonary Embolism: A Randomized Clinical Trial. JAMA. 2021;326(21):2141\u20139.","journal-title":"JAMA"},{"issue":"7","key":"473_CR34","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","volume":"112","author":"C Ay","year":"2008","unstructured":"Ay C, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703\u20138.","journal-title":"Blood"},{"key":"473_CR35","doi-asserted-by":"publisher","unstructured":"Gareev I, et al. MiRNAs and their role in venous thromboembolic complications. Diagnostics (Basel). 2023;13(21):3383. https:\/\/doi.org\/10.3390\/diagnostics13213383.","DOI":"10.3390\/diagnostics13213383"},{"issue":"2","key":"473_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","volume":"7","author":"L Gianni","year":"2007","unstructured":"Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol. 2007;7(2):67\u201371.","journal-title":"Cardiovasc Toxicol"},{"key":"473_CR37","doi-asserted-by":"publisher","unstructured":"Wang TF, Khorana AA, Carrier M. Thrombotic complications associated with immune checkpoint inhibitors. Cancers (Basel). 2021;13(18). https:\/\/doi.org\/10.3390\/cancers13184606.","DOI":"10.3390\/cancers13184606"},{"issue":"2","key":"473_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11883-018-0702-5","volume":"20","author":"SA Hassan","year":"2018","unstructured":"Hassan SA, et al. Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis. Curr Atheroscler Rep. 2018;20(2):10.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"473_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2147\/CIA.S3466","volume":"3","author":"S Gonnelli","year":"2008","unstructured":"Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interv Aging. 2008;3(4):647\u201357.","journal-title":"Clin Interv Aging"},{"issue":"7","key":"473_CR40","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jtha.2024.03.021","volume":"22","author":"P Bindal","year":"2024","unstructured":"Bindal P, et al. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024;22(7):2071\u201380.","journal-title":"J Thromb Haemost"},{"issue":"21","key":"473_CR41","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","volume":"5","author":"A Johnsrud","year":"2021","unstructured":"Johnsrud A, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5(21):4465\u201375.","journal-title":"Blood Adv"},{"issue":"4","key":"473_CR42","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","volume":"38","author":"Y Ando","year":"2020","unstructured":"Ando Y, et al. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs. 2020;38(4):1200\u20136.","journal-title":"Invest New Drugs"},{"issue":"4","key":"473_CR43","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","volume":"41","author":"SP Grover","year":"2021","unstructured":"Grover SP, et al. Cancer Therapy-Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291\u2013305.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"473_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2014.07.017","volume":"86","author":"WW Mellema","year":"2014","unstructured":"Mellema WW, et al. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. 2014;86(1):73\u20137.","journal-title":"Lung Cancer"},{"key":"473_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.euros.2021.07.007","volume":"32","author":"HS Haugnes","year":"2021","unstructured":"Haugnes HS, et al. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000\u20132014: A Population-based Cohort Study. Eur Urol Open Sci. 2021;32:19\u201327.","journal-title":"Eur Urol Open Sci"},{"key":"473_CR46","doi-asserted-by":"publisher","unstructured":"Poenou G, et al. Inhibition of factor XI: a new era in the treatment of venous thromboembolism in cancer patients? Int J Mol Sci. 2023;24(19). https:\/\/doi.org\/10.3390\/ijms241914433.","DOI":"10.3390\/ijms241914433"},{"key":"473_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"473_CR48","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","volume":"80","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, et al. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46\u201357.","journal-title":"Hypertension"},{"key":"473_CR49","doi-asserted-by":"publisher","unstructured":"Zeng P, Schmaier A. Ponatinib and other CML tyrosine kinase inhibitors in thrombosis. Int J Mol Sci. 2020;21(18). https:\/\/doi.org\/10.3390\/ijms21186556.","DOI":"10.3390\/ijms21186556"},{"key":"473_CR50","doi-asserted-by":"publisher","first-page":"1392859","DOI":"10.3389\/fendo.2024.1392859","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, et al. Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study. Front Endocrinol (Lausanne). 2024;15:1392859.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"473_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.thromres.2023.04.015","volume":"226","author":"N Potere","year":"2023","unstructured":"Potere N, et al. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial. Thromb Res. 2023;226:82\u20135.","journal-title":"Thromb Res"},{"issue":"17","key":"473_CR52","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599\u2013607.","journal-title":"N Engl J Med"},{"issue":"11","key":"473_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14779072.2020.1822167","volume":"18","author":"TF Overvad","year":"2020","unstructured":"Overvad TF, et al. Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. Expert Rev Cardiovasc Ther. 2020;18(11):791\u2013800.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"473_CR54","doi-asserted-by":"publisher","unstructured":"Yau CE, et al. Non-vitamin K antagonist oral anticoagulants versus low molecular weight heparin for cancer-related venous thromboembolic events: individual patient data meta-analysis. Cancers (Basel). 2023;15(24). https:\/\/doi.org\/10.3390\/cancers15245887.","DOI":"10.3390\/cancers15245887"},{"issue":"14","key":"473_CR55","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, et al. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025;392(14):1363\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"473_CR56","first-page":"55","volume":"13","author":"RA Byrne","year":"2024","unstructured":"Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13(1):55\u2013161.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"Suppl 1","key":"473_CR57","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.amjcard.2020.12.020","volume":"144","author":"PR Sinnaeve","year":"2021","unstructured":"Sinnaeve PR, Adriaenssens T. Dual Antiplatelet Therapy De-escalation Strategies. Am J Cardiol. 2021;144(Suppl 1):S23\u201331.","journal-title":"Am J Cardiol"},{"issue":"3","key":"473_CR58","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"issue":"9","key":"473_CR59","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9\u2013119.","journal-title":"Circulation"},{"issue":"Suppl B","key":"473_CR60","doi-asserted-by":"publisher","first-page":"B65","DOI":"10.1093\/eurheartjsupp\/suad070","volume":"25","author":"F Muscente","year":"2023","unstructured":"Muscente F, De Caterina R. The new in anticoagulation: factor XI inhibitors. Eur Heart J Suppl. 2023;25(Suppl B):B65\u20138.","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"473_CR61","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"473_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, et al. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020;323(2):130\u20139.","journal-title":"JAMA"},{"issue":"7","key":"473_CR63","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021;385(7):609\u201317.","journal-title":"N Engl J Med"},{"issue":"23","key":"473_CR64","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021;385(23):2161\u201372.","journal-title":"N Engl J Med"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00473-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00473-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00473-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:03:10Z","timestamp":1780624990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00473-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00473-3","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}